Werewolf Therapeutics Inc Dossier - Source-backed chat

Werewolf Therapeutics Inc

HOWLNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.92Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $44.8M

Shares Outstanding 50.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated cytokine therapies (INDUKINEs) and T-cell engagers (INDUCERs) using its proprietary PREDATOR platform. While clinical data for its lead candidates WTX-124 (IL-2) and WTX-330 (IL-12) have shown encouraging efficacy and favorable tolerability, the company is facing severe financial distress. In February 2026, Werewolf initiated a strategic review process, implemented a 64% workforce reduction, and disclosed substantial doubt about its ability to continue as a going concern. Although subsequent actions—such as the termination of its collaboration with Jazz Pharmaceuticals (reacquiring JZP898 for $21M upfront) and the repayment of its $31.4M K2 Health Ventures debt—have simplified its capital structure, the company's standalone survival depends entirely on the outcome of its strategic review, making it a highly speculative Hold.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$7.00

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The strategic review process fails to yield a viable transaction or partnership. The company runs out of cash, leading to liquidation, bankruptcy, or highly dilutive financing that wipes out existing equity holders.

Base CaseCentral scenario

The company successfully executes a strategic transaction (such as an asset sale, merger, or licensing partnership) that provides sufficient non-dilutive capital to advance its INDUKINE and INDUCER platforms, or is acquired at a modest premium to its current depressed market capitalization.

Bull CaseUpside scenario

The bull case relies on Werewolf successfully securing a strategic transaction (such as a company sale, merger, or lucrative licensing/collaboration agreements) that validates its PREDATOR platform and provides the non-dilutive funding necessary to advance its promising clinical candidates WTX-124 and WTX-330.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Encouraging clinical data for WTX-124, showing a 21% monotherapy objective response rate in heavily pretreated metastatic melanoma (30% in patients not primary resistant to immunotherapy) with an FDA-accepted 18 mg recommended dose.
Favorable safety profile for WTX-330 (IL-12 INDUKINE) with evidence of antitumor activity, avoiding the severe systemic toxicities historically associated with IL-12 therapies.
Simplified capital structure following the repayment of all outstanding debt under the K2 Health Ventures loan agreement in May 2026.

Key Investment Risks

Going concern risk with substantial doubt expressed by management regarding the company's ability to continue operations without securing additional funding or a strategic transaction.
High execution risk surrounding the ongoing strategic review process, with no guarantee of a favorable merger, acquisition, or partnership.
Severe workforce reduction (64% in February 2026) and lease terminations, which limit standalone operational and clinical development capabilities.

Thesis Invalidation Triggers

Failure to secure a strategic partner or buyer within the next 6-12 months.
Termination of the strategic review process without a transaction.
Inability to advance WTX-124 or WTX-330 due to lack of funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.